327 related articles for article (PubMed ID: 31134095)
1. DPP-4 Inhibitors as Potential Candidates for Antihypertensive Therapy: Improving Vascular Inflammation and Assisting the Action of Traditional Antihypertensive Drugs.
Zhang J; Chen Q; Zhong J; Liu C; Zheng B; Gong Q
Front Immunol; 2019; 10():1050. PubMed ID: 31134095
[TBL] [Abstract][Full Text] [Related]
2. A Cross-Sectional Study Comparing the Prevalence of Bullous Pemphigoid Autoantibodies in 275 Cases of Type II Diabetes Mellitus Treated With or Without Dipeptidyl Peptidase-IV Inhibitors.
Izumi K; Nishie W; Beniko M; Shimizu H
Front Immunol; 2019; 10():1439. PubMed ID: 31297116
[No Abstract] [Full Text] [Related]
3. Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury.
Penno G; Garofolo M; Del Prato S
Nutr Metab Cardiovasc Dis; 2016 May; 26(5):361-73. PubMed ID: 27105869
[TBL] [Abstract][Full Text] [Related]
4. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulatory activity of dipeptidyl peptidase-4 inhibitors in immune-related diseases.
Drakul M; Čolić M
Eur J Immunol; 2023 Dec; 53(12):e2250302. PubMed ID: 37732495
[TBL] [Abstract][Full Text] [Related]
6. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid, likely triggered by scabies, in a hemodialysis patient with human leukocyte antigen-DQB1*03:01.
Hibi A; Kasahara Y; Ishihara Y; Hata K; Hosokawa N; Nakagawa T
CEN Case Rep; 2020 Aug; 9(3):189-194. PubMed ID: 31993957
[TBL] [Abstract][Full Text] [Related]
7. Clinical features of dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid in Japan: A nationwide retrospective observational study.
Sugiyama S; Yamamoto T; Aoyama Y
J Dermatol; 2022 Jul; 49(7):697-702. PubMed ID: 35478414
[TBL] [Abstract][Full Text] [Related]
8. Dipeptidyl peptidase-4 inhibitors can inhibit angiotensin converting enzyme.
Abouelkheir M; El-Metwally TH
Eur J Pharmacol; 2019 Nov; 862():172638. PubMed ID: 31491403
[TBL] [Abstract][Full Text] [Related]
9. Renal Protective Effect of DPP-4 Inhibitors in Type 2 Diabetes Mellitus Patients: A Cohort Study.
Kim YG; Byun J; Yoon D; Jeon JY; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
J Diabetes Res; 2016; 2016():1423191. PubMed ID: 28119930
[No Abstract] [Full Text] [Related]
10. Contemporary Trends in Prescription of Dipeptidyl Peptidase-4 Inhibitors in the Context of US Food and Drug Administration Warnings of Heart Failure Risk.
Vaduganathan M; Singh A; Sharma A; Januzzi JL; Scirica BM; Butler J; Zannad F; McGuire DK; Cannon CP; Bhatt DL
Am J Cardiol; 2020 May; 125(10):1577-1581. PubMed ID: 32245636
[TBL] [Abstract][Full Text] [Related]
11. Case Report: Appearance of Various Disease-Specific Antibodies After the Onset of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.
Iwamoto Y; Anno T; Koyama K; Kawasaki F; Kaku K; Tomoda K; Sugiyama S; Aoyama Y; Kaneto H
Front Immunol; 2022; 13():843480. PubMed ID: 35309321
[TBL] [Abstract][Full Text] [Related]
12. Effects of dipeptidyl peptidase iv inhibition on arterial blood pressure.
Jackson EK; Dubinion JH; Mi Z
Clin Exp Pharmacol Physiol; 2008 Jan; 35(1):29-34. PubMed ID: 18047624
[TBL] [Abstract][Full Text] [Related]
13. Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system.
Aroor AR; Sowers JR; Jia G; DeMarco VG
Am J Physiol Heart Circ Physiol; 2014 Aug; 307(4):H477-92. PubMed ID: 24929856
[TBL] [Abstract][Full Text] [Related]
14. Direct effects of DPP-4 inhibition on the vasculature. Reconciling basic evidence with lack of clinical evidence.
Fadini GP; Albiero M; Avogaro A
Vascul Pharmacol; 2015 Oct; 73():1-3. PubMed ID: 26254108
[TBL] [Abstract][Full Text] [Related]
15. Risk of cardiovascular events associated with dipeptidyl peptidase-4 inhibitors in patients with diabetes with and without chronic kidney disease: A nationwide cohort study.
Huang TL; Hsiao FY; Chiang CK; Shen LJ; Huang CF
PLoS One; 2019; 14(5):e0215248. PubMed ID: 31112536
[TBL] [Abstract][Full Text] [Related]
16. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis.
Shah Z; Kampfrath T; Deiuliis JA; Zhong J; Pineda C; Ying Z; Xu X; Lu B; Moffatt-Bruce S; Durairaj R; Sun Q; Mihai G; Maiseyeu A; Rajagopalan S
Circulation; 2011 Nov; 124(21):2338-49. PubMed ID: 22007077
[TBL] [Abstract][Full Text] [Related]
17. Effects of Dipeptidyl Peptidase-4 Inhibitor and Angiotensin-Converting Enzyme Inhibitor on Experimental Diabetic Kidney Disease.
Al Tuhaifi T; Zhong J; Yang HC; Fogo AB
Lab Invest; 2024 Feb; 104(2):100305. PubMed ID: 38109999
[TBL] [Abstract][Full Text] [Related]
18. DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control.
Bae EJ
Arch Pharm Res; 2016 Aug; 39(8):1114-28. PubMed ID: 27502601
[TBL] [Abstract][Full Text] [Related]
19. Effect of Dipeptidyl Peptidase-4 Inhibitors on the Risk of Bone Fractures in a Korean Population.
Ustulin M; Park SY; Choi H; Chon S; Woo JT; Rhee SY
J Korean Med Sci; 2019 Sep; 34(35):e224. PubMed ID: 31496139
[TBL] [Abstract][Full Text] [Related]
20. Dipeptidyl peptidase IV (DPP-4) inhibition alleviates pulmonary arterial remodeling in experimental pulmonary hypertension.
Xu J; Wang J; He M; Han H; Xie W; Wang H; Kong H
Lab Invest; 2018 Oct; 98(10):1333-1346. PubMed ID: 29789684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
